CRISPR Therapeutics AG Shares Outstanding 2015-2021 | CRSP

CRISPR Therapeutics AG shares outstanding history from 2015 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • CRISPR Therapeutics AG shares outstanding for the quarter ending June 30, 2021 were 0.080B, a 30.98% increase year-over-year.
  • CRISPR Therapeutics AG 2020 shares outstanding were 0.066B, a 15.84% increase from 2019.
  • CRISPR Therapeutics AG 2019 shares outstanding were 0.057B, a 18.7% increase from 2018.
  • CRISPR Therapeutics AG 2018 shares outstanding were 0.048B, a 19.74% increase from 2017.
CRISPR Therapeutics AG Annual Shares Outstanding
(Millions of Shares)
2020 66
2019 57
2018 48
2017 40
2016 12
2015 5
2014 4
CRISPR Therapeutics AG Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 80
2021-03-31 75
2020-12-31 66
2020-09-30 70
2020-06-30 61
2020-03-31 61
2019-12-31 57
2019-09-30 58
2019-06-30 53
2019-03-31 52
2018-12-31 48
2018-09-30 47
2018-06-30 47
2018-03-31 46
2017-12-31 40
2017-09-30 40
2017-06-30 40
2017-03-31 40
2016-12-31 12
2016-09-30 5
2016-06-30
2016-03-31 6
2015-12-31
2015-09-30 6
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.935B $0.001B
CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29